ESRD

Cadrenal Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Wednesday, February 1, 2023
Boston Medical Center, Health, ESRD, Atrial fibrillation, Kidney disease, Section, SAB, Patient, Ventricular fibrillation, Nephrology, United States Air Force Scientific Advisory Board, Therapy, Associate, Baylor College of Medicine, Thrombosis, Michael G. DeGroote School of Medicine, Pharmaceutical industry, Management

"We have assembled a world-class group of anticoagulant, medical and scientific experts to provide strategic guidance to Cadrenal," commented Quang Pham, Chief Executive Officer of Cadrenal.

Key Points: 
  • "We have assembled a world-class group of anticoagulant, medical and scientific experts to provide strategic guidance to Cadrenal," commented Quang Pham, Chief Executive Officer of Cadrenal.
  • "Cadrenal is fortunate to have engaged thought leaders in the key disciplines involved in our tecarfarin program.
  • We look forward to their guidance as we advance this program to completion," said Dr. Douglas Losordo, Chief Medical Officer of Cadrenal.
  • Members of the Cadrenal SAB include:
    Section Editor for Thrombosis and Haemostasis and the Director of the Thrombosis and Anticoagulation Service at Boston Medical Center.

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation

Retrieved on: 
Monday, January 23, 2023
Therapy, Biomarker, Marketing, Ventricular fibrillation, Collection, Stroke, Priority review, New Drug Application, NDA, Kidney disease, ODD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Accelerated approval (FDA), ESRD, Duke University, Plasma protein binding, FDA, Rare, White Light Rock & Roll Review, Patient, Atrial fibrillation, Fast Track, Food, Communication, Tecarfarin, Fast track (FDA), Assistant, Pharmaceutical industry, Medical device, Medicine

Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Key Points: 
  • Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
  • The purpose of Fast Track is to get important new drugs to the patient earlier.
  • Fast Track addresses a broad range of serious conditions.
  • The FDA had previously granted an Orphan Drug Designation (ODD) for tecarfarin.

ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease

Retrieved on: 
Tuesday, January 10, 2023
Kidney, COVID, Type 2 diabetes, Kidney failure, Dialysis, Trial of the century, ESRD, Quality of life, San Rafael, California, Renal replacement therapy, CT, Glomerular filtration rate, EGFR, Manuscript, CKD, Chronic kidney disease, Patient, Observation, DOI, REACT, DKD, Data analysis, Late, Myocardial infarction, Pharmaceutical industry, Journal

WINSTON-SALEM, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the publication of the trial design and early data analysis from REGEN-003, a Phase 2 clinical study of Renal Autologous Cell Therapy (REACT®), in the Journal of Blood Purification. The paper, titled Renal Autologous Cell Therapy (REACT) in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis, was published online and will appear later this year in the print edition of the Journal (DOI: doi.org/10.1159/000527582).

Key Points: 
  • The paper, titled Renal Autologous Cell Therapy (REACT) in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis, was published online and will appear later this year in the print edition of the Journal (DOI: doi.org/10.1159/000527582 ).
  • “This is a high-risk patient population with seriously reduced kidney function.
  • At 15 months, two patients (20%) had preservation of their kidney function and had not advanced to renal replacement therapy.
  • We believe that REACT has the potential to have a significant, positive impact on patients’ health and quality of life.

WellSky® Partners With Panoramic Health to Deliver Superior Healthcare and Improve Outcomes for Patients Suffering From Chronic Kidney Disease

Retrieved on: 
Monday, January 9, 2023
Technology, Nursing, Hospitals, Health Technology, Health Insurance, Software, Practice Management, Managed Care, Health, Ecosystem, Panorama, Partnership, Dialysis, Health, ESRD, Quality of life, CKD, Chronic kidney disease, Patient, Hospital, Medicine

Having exclusive relationships with over 800 nephrology providers across 19 states, Panoramic Health delivers comprehensive patient-centric care coordination and improved access to care to slow disease progression and improve the quality of life for CKD and ESRD patients.

Key Points: 
  • Having exclusive relationships with over 800 nephrology providers across 19 states, Panoramic Health delivers comprehensive patient-centric care coordination and improved access to care to slow disease progression and improve the quality of life for CKD and ESRD patients.
  • “Partnering with WellSky creates new competitive advantages for our organization to provide patient-centric value-based care,” said Chris Schmaltz, chief value-based care officer at Panoramic Health.
  • “We’re thrilled to partner with a forward-thinking organization like Panoramic Health,” said Andy Eilert, president, emerging markets at WellSky.
  • “The combination of their cutting-edge analytics and care management tools and WellSky’s connected ecosystem means more patients with chronic kidney disease are able to get critical interventions that improve their quality of life.”

Insights on the Renal Replacement Therapy Global Market to 2028 - Featuring Asahi Kasei, Baxter, CryoLife and DaVita Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Health, General Health, Hemofiltration, CRRT, Septic shock, PD, Blood, Kidney, Dialysis, Food, AKI, Renal replacement therapy, Incidence, Geography, Peritoneal dialysis, COVID-19, Myasthenia gravis, Jean-Louis Vincent, News, Conditional sentence, Abdomen, Travel, Growth, Patient, ESRD, HD, Clifton Springs Hospital & Clinic, FDA, Hospital, Baxter International, Food and Drug Administration, Chronic kidney disease, Quality of life, EUA, Acute kidney injury, Prevalence, Survival, Pharmaceutical industry, Medical device, Marketing, Sepsis, ICU

Additionally, the increasing prevalence of chronic disease is expected to drive the growth of the renal replacement therapy market.

Key Points: 
  • Additionally, the increasing prevalence of chronic disease is expected to drive the growth of the renal replacement therapy market.
  • However, the high cost of renal replacement therapy procedures is expected to restrain the market growth in the forecasted period.
  • Additionally, Strict regulatory guidelines for continuous renal replacement therapy, and the Lack of skilled professionals to perform constant renal replacement therapy are hampering the growth of the renal replacement therapy market.
  • The global renal replacement therapy market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market.

MayaMD's Pioneering AI Healthcare Platform Solidifies Leadership Role in Value Based Care with Top Nephrology Group NKDHC

Retrieved on: 
Wednesday, January 4, 2023
CKD, Carnegie Mellon University, Patient, UCLA, Nephrology, UCSF, Chronic kidney disease, Disease, Partnership, AI, Hospital, Risk, MD, Multimedia, ESRD, Triage, Natural language processing, CB Insights, Pharmaceutical industry

"We are so grateful and excited to work with this phenomenal group of nephrologists and help support their patients."

Key Points: 
  • "We are so grateful and excited to work with this phenomenal group of nephrologists and help support their patients."
  • 37 million people have chronic kidney disease and 1 in 3 Americans are at risk for it.
  • MayaMD offers providers a unique way of helping them embrace value based care with ways that improve care quality, limit unnecessary expensive care like avoidable ER visits, and helping to reduce hospital readmission rates.
  • MayaMD is an award winning AI patient engagement company that helps providers embrace value based care.

Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic

Retrieved on: 
Monday, January 2, 2023
EMA, Quality of life, Mortality, Antibody, Priority, Medical research, Transplant, Patient, European, Nasdaq Stockholm, Dialysis, Kidney transplantation, Chronic kidney disease, Veni, vidi, vici, Medication package insert, Degenerative disease, Hospital, Kidney, Immunoglobulin G, Risk, Medicine, Safety, Kidney failure, ESRD, European Medicines Agency, State, Kidney disease, European Marketing Research Centre, Survival, Drug, Czech Republic, Human leukocyte antigen, Research, Cancer, DSA, Hansa, NIH, Health insurance, Dentistry, Pharmaceutical industry, Medical device, Agency

"We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.

Key Points: 
  • "We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.
  • These patients have a serious disease burden and unmet needs and this decision is a significant milestone for them", says Søren Tulstrup, President and CEO, Hansa Biopharma.
  • "For Hansa, this decision is well aligned with  our vision: A world where patients with rare immunologic diseases can lead long and healthy lives."
  • Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S.

Gold Kidney Health Plan Raises $60 Million from Chicago Pacific Founders in Partnership to Serve Patients with Kidney Diseases

Retrieved on: 
Tuesday, December 27, 2022
Centers for Medicare & Medicaid Services, CMS, Patient, Business development, Nephrology, Dialysis, Health, Chronic kidney disease, Kidney, AI, Kidney disease, Partnership, Transport, Medicare, End, CPF, ESRD, Partner (business rank), Ageing, PCP, Banner Health, Gold, Primary care, Health insurance

As a Special Needs Plan, Gold Kidney can enroll patients all year round.

Key Points: 
  • As a Special Needs Plan, Gold Kidney can enroll patients all year round.
  • Gold Kidney was seeded by over 100 nephrologists discouraged with the limited Medicare plan options for their Chronic Kidney Disease and ESRD patients.
  • "CPF believes that Gold Kidney is a market leading Medicare Advantage product, purpose built to uniquely serve patients with kidney disease.
  • Gold Kidney Health Plan is a Medicare Advantage Plan offering Medicare Advantage products for beneficiaries with Chronic Special Needs.

EQS-News: Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive

Retrieved on: 
Sunday, December 18, 2022
ESRD, Centers for Medicare & Medicaid Services, AKBA, Dialysis, PPS, Medicine, Kidney, Advertising, Pharmacotherapy, CKD, FDA, Hyperphosphatemia, Medicare Part D, CMS, News, Insurance, Biotechnology, Health equity, Environment, Medicare, Prospective payment system, Lanthanum, Acute kidney injury, Disease, Gastrointestinal tract, Therapy, Chronic kidney disease, Prescription, UNI, Risk, Patient, Health insurance, Generic drug, Pharmaceutical industry

In October, the CMS published its “Final Rule” updating payment rates and policies for the PPS for end-stage renal disease (ESRD), for the calendar year 2023.

Key Points: 
  • In October, the CMS published its “Final Rule” updating payment rates and policies for the PPS for end-stage renal disease (ESRD), for the calendar year 2023.
  • Renazorb utilizes a proprietary nanoparticle technology being developed by Unicycive for the treatment of hyperphosphatemia in CKD patients on dialysis.
  • Renazorb also has an added convenience for patients since it is swallowed with water instead of having to be chewed.
  • “Gaining early patient access and reimbursement for newly launched branded drugs can be a challenge” stated Doug Jermasek, Executive Vice President at Unicycive.

American Endovascular & Amputation Prevention LLC Transitions to eClinicalWorks to Eliminate Administrative Burden

Retrieved on: 
Wednesday, December 14, 2022
Technology, Health Technology, Software, Practice Management, Other Health, Internet, Health, General Health, Data Management, ENDO, Cloud, Moyamoya disease, Physician, EHR, Electronic health record, ESRD, PAE, PRISMA, Patient, 3D ultrasound, Prostatic artery embolization, Automation, Amputation, Multimedia, Uterine artery embolization, PAD, Ischemia, Practice management software, CLI, Database, Venous insufficiency, Robotic process automation, Medical imaging, Medicine

eClinicalWorks , the largest ambulatory cloud EHR, today announced that American Endovascular & Amputation Prevention LLC transitioned to eClinicalWorks multi-dimensional EHR solution.

Key Points: 
  • eClinicalWorks , the largest ambulatory cloud EHR, today announced that American Endovascular & Amputation Prevention LLC transitioned to eClinicalWorks multi-dimensional EHR solution.
  • This added administrative work for physicians and slowed down our practice workflows, said Deborah Helmer, COO of American Endovascular.
  • American Endovascular affiliated physicians are at the forefront of the battle to prolong life by preventing amputations.
  • The American Endovascular affiliated physicians are proud to offer high-quality, compassionate endovascular care for patients throughout New Jersey, New York, and Ohio.